Although IL-17 has these neuroprotective effects, mice treated with IL-33 showed an exacerbation of post-stroke pulmonary bacterial infection associated with greater functional impairment and mortality after 24 hours, suggesting exacerbation of systemic immunosuppression after ischemic stroke (163). Here, IL17A is linked to ischemic stroke.